Table 1

Demographic and clinical characteristics of systemic lupus erythematosus patients
Characteristic Value
Age, years, mean ± SD 40.4 ± 14.5
Gender, female/male, n (%) 56 (91.8%)/5 (8.2%)
Disease duration years, mean ± SD 5.4 ± 4.9
Anti-ds DNA Ab-positive, n (%) 23 (62.3%)
C3, mean ± SD 90.5 ± 26.6
C4, mean ± SD 14.3 ± 7.1
CH50, mean ± SD 110.6 ± 31.9
SLEDAI, mean ± SD 4.2 ± 4.2
ECLAM, mean ± SD 1.9 ± 1.9
SIS, mean ± SD 3.6 ± 2.9
Current prednisone dose, mg/day, mean ± SD 10.4 ± 15.3
Concurrent immunosuppressive therapy, n (%)
Hydroxychloroquine 22 (36.1%)
Mycophenolate mofetil 9 (14.8%)
Cyclophosphamide 6 (9.8%)
Azathioprine 8 (13.1%)
Methotrexate 5 (8.2%)
Organ involvement, n (%)
Skin/active 37 (60.7.1%)/8 (13.1%)
Hematologic/active 23 (37.7%)/10 (16.4%)
Arthritis/active 22 (36.1%)/3 (4.9%)
Serositis/active 8 (13.1%)/2 (3.3%)
Renal/active 25 (40.9%)/13 (21.3%)

SLEDAI, systemic lupus erythematosus disease activity index; ECLAM, European Consensus Lupus Activity Measurement; SIS, systemic lupus erythematosus index score.

Bonelli et al.

Bonelli et al. Arthritis Research & Therapy 2014 16:R104   doi:10.1186/ar4553

Open Data